ACB saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 71 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where ACB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 179 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 82 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
The 10-day RSI Indicator for ACB moved out of overbought territory on October 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 17 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 42 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for ACB crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.488) is normal, around the industry mean (8.346). P/E Ratio (-2.093) is within average values for comparable stocks, (-1.638). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The RSI Oscillator for OGI moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 33 of the 36 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on OGI as a result. In 73 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for OGI just turned positive on October 20, 2026. Looking at past instances where OGI's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +2.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGI advanced for three days, in 169 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
OGI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
OGI moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OGI entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.277) is normal, around the industry mean (8.542). P/E Ratio (1.527) is within average values for comparable stocks, (-1.854). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.650) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. OGI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ACB | OGI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 88 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 46 | |
PRICE GROWTH RATING 1..100 | 41 | 76 | |
P/E GROWTH RATING 1..100 | 91 | 97 | |
SEASONALITY SCORE 1..100 | 12 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (24) in the Pharmaceuticals Other industry is in the same range as OGI (37) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as OGI (100) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.
OGI's SMR Rating (46) in the null industry is somewhat better than the same rating for ACB (96) in the Pharmaceuticals Other industry. This means that OGI’s stock grew somewhat faster than ACB’s over the last 12 months.
ACB's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for OGI (76) in the null industry. This means that ACB’s stock grew somewhat faster than OGI’s over the last 12 months.
ACB's P/E Growth Rating (91) in the Pharmaceuticals Other industry is in the same range as OGI (97) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.
| ACB | OGI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 2 days ago 88% |
| Momentum ODDS (%) | 1 day ago 79% | 2 days ago 78% |
| MACD ODDS (%) | 1 day ago 90% | 2 days ago 89% |
| TrendWeek ODDS (%) | 1 day ago 81% | 2 days ago 80% |
| TrendMonth ODDS (%) | 1 day ago 78% | 2 days ago 84% |
| Advances ODDS (%) | 4 days ago 76% | 2 days ago 79% |
| Declines ODDS (%) | 12 days ago 84% | 8 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 90% | 2 days ago 85% |
| Aroon ODDS (%) | 1 day ago 71% | 2 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while OGI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 6 TA indicator(s) are bullish while OGI’s TA Score has 5 bullish TA indicator(s).
ACB (@Pharmaceuticals: Generic) experienced а +4.64% price change this week, while OGI (@Pharmaceuticals: Generic) price change was +0.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.14%. For the same industry, the average monthly price growth was -9.43%, and the average quarterly price growth was +3.28%.
ACB is expected to report earnings on Nov 12, 2026.
OGI is expected to report earnings on Dec 15, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, OGI has been closely correlated with SNDL. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if OGI jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To OGI | 1D Price Change % | ||
|---|---|---|---|---|
| OGI | 100% | -2.85% | ||
| SNDL - OGI | 67% Closely correlated | -4.62% | ||
| ACB - OGI | 64% Loosely correlated | -0.49% | ||
| CGC - OGI | 58% Loosely correlated | -3.33% | ||
| TLRY - OGI | 50% Loosely correlated | -4.17% | ||
| TRLV - OGI | 49% Loosely correlated | -3.02% | ||
More | ||||